Halcygen's anti-fungal drug successfully evaluated
(RWE Aust Business News) Halcygen Pharmaceuticals Ltd (ASX:HGN) has announced that its lead product, an anti-fungal drug SUBA-Itraconazole, has successfully been evaluated in the first of two pharmacokinetic
studies in humans.
The trial demonstrated that Halcygen's formulation of Itraconazole is absorbed twice as effectively as the lead marketed form of the drug, Sporonox.
Sales of the anti-fungal drug Itraconazole/Sporonox were in excess of $US600 million last year.
This trial confirms the results of three previous trials conducted by Halcygen's licence partner Mayne Pharma International.
The formulation provides greater reliability in absorption and as a result more reliable blood levels of the anti-fungal agent.
Shares of Halcygen rose 4c to 55c this morning.
Add to My Watchlist
What is My Watchlist?